19.59
-0.65(-3.21%)
Currency In USD
Address
18 Campus Boulevard
Newtown Square, 19073
United States of America
Phone
628-277-4836
Website
Sector
Healthcare
Industry
Biotechnology
Employees
52
First IPO Date
January 26, 2024
| Name | Title | Pay | Year Born |
| Dr. Zhengbin Yao Ph.D. | Co-Founder, Chairman, President & Chief Executive Officer | 810,606 | 1966 |
| Ms. Robin LaChapelle M.A. | Co-Founder & Chief Operating Officer | 586,453 | 1973 |
| Mr. Winston Kung M.B.A. | Chief Financial Officer & Treasurer | 645,999 | 1976 |
| Dr. Stuart Lutzker M.D., Ph.D. | Co-Founder, President of Research & Development and Director | 688,510 | 1961 |
| Ms. Yang Wang Ph.D. | Chief Technology Officer | 0 | N/A |
| Dr. James Paul Kastenmayer J.D., Ph.D. | General Counsel & Secretary | 0 | 1972 |
| Ms. Meghna Chowdary | Senior Vice President of Commercial Strategy | 0 | N/A |
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.